You are here: Industry Insights > CureVac

News List

CureVac Appoints Dr. Malte Greune as COO contractpharma
July 01, 2021
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Dr. Malte Greune as chief operating officer (COO) effective July 1, 2021.
CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV worldpharmanews
June 21, 2021
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced results of the second interim analysis of its international pivotal Phase 2b/3 study in ...
CureVac’s COVID-19 vaccine misses the mark in late-stage study pharmatimes
June 18, 2021
German biopharma company CureVac has announced that its COVID-19 vaccine candidate CVnCoV missed the prespecified statistical success criteria in a Phase II/III study.
CureVac's COVID-19 Vaccine Only 47 Percent Effective drugs
June 18, 2021
CureVac's COVID-19 vaccine was only 47 percent effective in a clinical trial, according to preliminary results released Wednesday that suggest the vaccine may not help fill the worldwide need for vaccines.
CureVac blames variants for COVID-19 vaccine fail in pivotal trial firstwordpharma
June 17, 2021
CureVac's stock was cut in half on Wednesday after the company reported that its vaccine candidate CVnCoV was only 47% effective at preventing COVID-19 disease of any severity in a second interim analysis, falling short of pre-specified statistical.
CureVac Appoints Chief Development Officer contractpharma
June 03, 2021
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Klaus Edvardsen, MD, PhD, as chief development officer.
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation firstwordpharma
May 31, 2021
CVAC today announced that the independent DSMB has confirmed that the pivotal Phase 2b/3 study for CureVac's first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases.
Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study worldpharmanews
May 19, 2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that ...
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data pharmatimes
May 17, 2021
GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced May 13.
CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic worldpharmanews
April 26, 2021
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV ...

Previous page 1 2 3 4 5 Next page